<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Paisana E</submitter><funding>Fundação para a Ciência e a Tecnologia</funding><pagination>vdad048</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10195208</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>5(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Despite current improvements in systemic cancer treatment, brain metastases (BM) remain incurable, and there is an unmet clinical need for effective targeted therapies.&lt;h4>Methods&lt;/h4>Here, we sought common molecular events in brain metastatic disease. RNA sequencing of thirty human BM identified the upregulation of &lt;i>UBE2C&lt;/i>, a gene that ensures the correct transition from metaphase to anaphase, across different primary tumor origins.&lt;h4>Results&lt;/h4>Tissue microarray analysis of an independent BM patient cohort revealed that high expression of UBE2C was associated with decreased survival. UBE2C-driven orthotopic mouse models developed extensive leptomeningeal dissemination, likely due to increased migration and invasion. Early cancer treatment with dactolisib (dual P</pubmed_abstract><journal>Neuro-oncology advances</journal><pubmed_title>UBE2C promotes leptomeningeal dissemination and is a therapeutic target in brain metastatic disease.</pubmed_title><pmcid>PMC10195208</pmcid><funding_grant_id>PD/BD/128288/2017</funding_grant_id><funding_grant_id>PTDC/MEDONC/</funding_grant_id><pubmed_authors>Roque R</pubmed_authors><pubmed_authors>Qin N</pubmed_authors><pubmed_authors>Picard D</pubmed_authors><pubmed_authors>Cascao R</pubmed_authors><pubmed_authors>Pauck D</pubmed_authors><pubmed_authors>Doutel D</pubmed_authors><pubmed_authors>Pimentel J</pubmed_authors><pubmed_authors>Ruivo P</pubmed_authors><pubmed_authors>Remke M</pubmed_authors><pubmed_authors>Barreto C</pubmed_authors><pubmed_authors>Paisana E</pubmed_authors><pubmed_authors>Cabecadas J</pubmed_authors><pubmed_authors>Custodia C</pubmed_authors><pubmed_authors>Miguens J</pubmed_authors><pubmed_authors>Faria CC</pubmed_authors><pubmed_authors>Carvalho T</pubmed_authors><pubmed_authors>Barata JT</pubmed_authors></additional><is_claimable>false</is_claimable><name>UBE2C promotes leptomeningeal dissemination and is a therapeutic target in brain metastatic disease.</name><description>&lt;h4>Background&lt;/h4>Despite current improvements in systemic cancer treatment, brain metastases (BM) remain incurable, and there is an unmet clinical need for effective targeted therapies.&lt;h4>Methods&lt;/h4>Here, we sought common molecular events in brain metastatic disease. RNA sequencing of thirty human BM identified the upregulation of &lt;i>UBE2C&lt;/i>, a gene that ensures the correct transition from metaphase to anaphase, across different primary tumor origins.&lt;h4>Results&lt;/h4>Tissue microarray analysis of an independent BM patient cohort revealed that high expression of UBE2C was associated with decreased survival. UBE2C-driven orthotopic mouse models developed extensive leptomeningeal dissemination, likely due to increased migration and invasion. Early cancer treatment with dactolisib (dual P</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan-Dec</publication><modification>2026-05-28T22:59:55.615Z</modification><creation>2025-04-04T23:44:41.208Z</creation></dates><accession>S-EPMC10195208</accession><cross_references><pubmed>37215954</pubmed><doi>10.1093/noajnl/vdad048</doi></cross_references></HashMap>